Future perspectives of personalized oncology
- PMID: 20698168
Future perspectives of personalized oncology
Abstract
Based upon an individual's molecular make-up, personalized molecular medicine provides information regarding the origin of disease, its treatment and progression, while personalized molecular pharmacology advises on drug prescription and patient response to it, thus ensuring drug effectiveness and preventing drug toxicity or lack of response. Interindividual differences in drug responses are mostly due to structural variation in parts of genome, e.g. in genes participating in drug metabolism, transport or targeting. However, a wide variety of diseases and accompanying health conditions, including patient's therapy or drug response, also have epigenetic or epigenomic etiology. High priority for personalized oncologic research stems from inter/intraindividual tumor heterogeneity provoked by gradual acquisition of multiple random, or programmed mutations and rearrangements as well as epigenetic alterations or by stochastic fluctuations in cell components, all in tight feedback interaction with tumor's environmental or therapy conditions. Natural selection subsequently shapes inter/intraindividual tumor heterogeneity by promoting clonal expansion of cells that have acquired advantageous mutations for tumor population. Hence, the main rationale of personalized molecular oncology should focus on treating disease by relying on relevant structure and state of patient's whole molecular network (genome/transcriptome/RNome/proteome/metabolome/metabonome) in interaction with its unique environmental conditions, thus implying right therapy for the right patient at the right dose and time. The future of personalized oncology should therefore rely on the methods of systems biology applied in cytology and pathology in order to develop and utilize the efficient and effective diagnostic, prognostic and predictive biomarkers, consequently providing the molecular information on tumor origin, its potential for metastasis, adequate therapy, tumor specific therapy responsiveness, and the probability of its recurrence.
Similar articles
-
Personalized oncology: recent advances and future challenges.Metabolism. 2013 Jan;62 Suppl 1:S11-4. doi: 10.1016/j.metabol.2012.08.016. Epub 2012 Sep 19. Metabolism. 2013. PMID: 22999010 Review.
-
Novel clinico-genome network modeling for revolutionizing genotype-phenotype-based personalized cancer care.Expert Rev Mol Diagn. 2010 Jan;10(1):33-48. doi: 10.1586/erm.09.69. Expert Rev Mol Diagn. 2010. PMID: 20014921 Review.
-
Omics-based nanomedicine: the future of personalized oncology.Cancer Lett. 2014 Sep 28;352(1):126-36. doi: 10.1016/j.canlet.2013.07.029. Epub 2013 Aug 11. Cancer Lett. 2014. PMID: 23941830 Review.
-
Personalized cancer medicine: from molecular diagnostics to targeted therapy with natural products.Planta Med. 2010 Aug;76(11):1143-54. doi: 10.1055/s-0030-1249937. Epub 2010 May 19. Planta Med. 2010. PMID: 20486071 Review.
-
Personalized medicine in oncology: tailoring the right drug to the right patient.Biomark Med. 2010 Aug;4(4):523-33. doi: 10.2217/bmm.10.66. Biomark Med. 2010. PMID: 20701441 Review.
Cited by
-
A receptor tyrosine kinase network composed of fibroblast growth factor receptors, epidermal growth factor receptor, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, and hepatocyte growth factor receptor drives growth and survival of head and neck squamous carcinoma cell lines.Mol Pharmacol. 2013 Apr;83(4):882-93. doi: 10.1124/mol.112.084111. Epub 2013 Jan 31. Mol Pharmacol. 2013. PMID: 23371912 Free PMC article.
-
Exploitation of Gene Expression and Cancer Biomarkers in Paving the Path to Era of Personalized Medicine.Genomics Proteomics Bioinformatics. 2017 Aug;15(4):220-235. doi: 10.1016/j.gpb.2016.11.005. Epub 2017 Aug 13. Genomics Proteomics Bioinformatics. 2017. PMID: 28813639 Free PMC article. Review.
-
State of the art in silico tools for the study of signaling pathways in cancer.Int J Mol Sci. 2012;13(6):6561-6581. doi: 10.3390/ijms13066561. Epub 2012 May 29. Int J Mol Sci. 2012. PMID: 22837650 Free PMC article. Review.
-
Pharmacokinetically guided algorithm of 5-fluorouracil dosing, a reliable strategy of precision chemotherapy for solid tumors: a meta-analysis.Sci Rep. 2016 May 27;6:25913. doi: 10.1038/srep25913. Sci Rep. 2016. PMID: 27229175 Free PMC article.
-
Metabolomic biomarkers of pancreatic cancer: a meta-analysis study.Oncotarget. 2017 Aug 18;8(40):68899-68915. doi: 10.18632/oncotarget.20324. eCollection 2017 Sep 15. Oncotarget. 2017. PMID: 28978166 Free PMC article.